The overlapping and specific TFA signatures in different types of human cancers provide a transcription factor-based guide to the mechanisms of cancer development caused by PTEN loss, and offer TFA-based rationales for designing new therapeutic regimen for treating PTEN null cancers and also monitoring PI3K pathway targeted treatment responses. Here, PTEN is linked to cancer.